Related Experiment Video
Updated: May 23, 2026
Induction and Analysis of Epithelial to Mesenchymal Transition
Published on: August 27, 2013
A cell-based small molecule screening method for identifying inhibitors of epithelial-mesenchymal transition in
Kian-Ngiap Chua1, Wen-Jing Sim, Victor Racine
1Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
Abstract:
Epithelial Mesenchymal Transition (EMT) is a crucial mechanism for carcinoma progression, as it provides routes for in situ carcinoma cells to dissociate and become motile, leading to localized invasion and metastatic spread. Targeting EMT therefore represents an important therapeutic strategy for cancer treatment. The discovery of oncogene addiction in sustaining tumor growth has led to the rapid development of targeted therapeutics. Whilst initially optimized as anti-proliferative agents, it is likely that some of these compounds may inhibit EMT initiation or sustenance, since EMT is also modulated by similar signaling pathways that these compounds were designed to target. We have developed a novel screening assay that can lead to the identification of compounds that can inhibit EMT initiated by growth factor signaling. This assay is designed as a high-content screening assay where both cell growth and cell migration can be analyzed simultaneously via time-course imaging in multi-well plates. Using this assay, we have validated several compounds as viable EMT inhibitors. In particular, we have identified compounds targeting ALK5, MEK, and SRC as potent inhibitors that can interfere with EGF, HGF, and IGF-1 induced EMT signaling. Overall, this EMT screening method provides a foundation for improving the therapeutic value of recently developed compounds in advanced stage carcinoma.
Insights
Scientists developed a new assay to find drugs that stop epithelial mesenchymal transition (EMT), a key process in cancer spread. This method identified compounds targeting ALK5, MEK, and SRC as effective EMT inhibitors for advanced carcinomas.
Area of Science:
- Oncology
- Cell Biology
- Pharmacology
Background:
- Epithelial Mesenchymal Transition (EMT) is critical for carcinoma progression, enabling cell dissociation, motility, invasion, and metastasis.
- Targeting EMT is a key therapeutic strategy for cancer treatment, especially given the success of targeted therapies for oncogene addiction.
- Existing targeted therapeutics, initially for anti-proliferation, may also inhibit EMT due to shared signaling pathways.
Purpose of the Study:
- To develop and validate a novel high-content screening assay for identifying compounds that inhibit growth factor-induced Epithelial Mesenchymal Transition (EMT).
- To assess the potential of existing targeted therapeutics to inhibit EMT.
- To provide a foundation for enhancing the therapeutic value of compounds in advanced stage carcinoma treatment.
Main Methods:
- Development of a novel high-content screening assay enabling simultaneous analysis of cell growth and migration via time-course imaging in multi-well plates.
- Utilized the assay to screen for compounds inhibiting EMT initiated by growth factor signaling (EGF, HGF, IGF-1).
- Validated identified compounds as EMT inhibitors, focusing on those targeting ALK5, MEK, and SRC signaling pathways.
Main Results:
- Successfully developed and validated a novel high-content screening assay for EMT inhibition.
- Identified several compounds capable of inhibiting EMT.
- Specifically, compounds targeting ALK5, MEK, and SRC demonstrated potent inhibition of EGF, HGF, and IGF-1 induced EMT signaling.
Conclusions:
- The developed EMT screening assay is effective for identifying novel EMT inhibitors.
- Compounds targeting ALK5, MEK, and SRC are potent inhibitors of growth factor-induced EMT.
- This screening method offers a foundation for improving the therapeutic efficacy of targeted agents in advanced carcinomas.
More Related Videos
06:02Development of an In Vitro Assay to Evaluate Contractile Function of Mesenchymal Cells that Underwent Epithelial-Mesenchymal Transition
Published on: June 10, 2016
06:54Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
